Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Pretreatment for RAI in Advanced Differentiated Thyroid Cancer
NCT04180007Phase 2Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in differentiated thyroid cancer (DTC), sponsored by Nanjing First Hospital. Primary endpoint: Overall Response Rate at 4 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04180007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180007.